FDA approves Alzheimer's disease treatment developed by a Japanese company
Aducanumab (trade name: ADUHELM), a treatment for Alzheimer's disease jointly developed by
FDA Grants Accelerated Approval for Alzheimer's Drug | FDA
https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug
ADUHELM ™ Rapidly approved by the US FDA as the first and only treatment for the pathology of Alzheimer's disease | News Release: 2021 | Eisai Co., Ltd.
FDA grants accelerated approval for ADUHELM ™ as the first and only Alzheimer's disease treatment to address a defining pathology of the disease | Biogen
https://investors.biogen.com/news-releases/news-release-details/fda-grants-accelerated-approval-aduhelmtm-first-and-only
The FDA announced on June 7, 2021 that it has approved aducanumab, a treatment for Alzheimer's disease jointly developed by Eisai and Biogen.
According to Eisai, aducanumab is a drug that treats Alzheimer's disease by reducing amyloid β plaque , which is known to be abundant in the brains of Alzheimer's disease patients. Haruo Naito, CEO of Eisai, said, 'Eisai has been working on the development of drugs for Alzheimer's disease since the early 1980s. With the approval of ADUHELM, we were able to open a new page in the history of Alzheimer's disease treatment. I am very happy. '
According to CNBC, the suggested retail price for aducanumab is $ 4312, and the annual cost is $ 56,000. Regarding this price, Biogen CEO Michel Vounatsos said , 'I think it's a fair price,' and has stated that it will not raise the price for four years from 2021. Eisai's subsidiaries Eisai, Inc. and Biogen have also announced a support program for people who do not have adequate medical services, and will work to provide aducanumab to many Alzheimer's patients. is.
In addition, even before the advent of aducanumab, it was pointed out that 'good sleep' may help reduce the risk of Alzheimer's disease, and the theory that periodontal disease bacteria are the cause of Alzheimer's disease has been advocated. It is active and there are high expectations for reducing the risk of Alzheimer's disease.
'Periodontal disease bacteria' have emerged as a candidate cause of Alzheimer's disease, and toothpaste may help prevent Alzheimer's disease --GIGAZINE
Related Posts:
in Note, Posted by log1o_hf